Online inquiry

IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8973MR)

This product GTTS-WQ8973MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL22 gene. The antibody can be applied in Inflammatory conditions research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_020525.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50616
UniProt ID Q9GZX6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8973MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2980MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ANB020
GTTS-WQ10626MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3303560
GTTS-WQ1123MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-927
GTTS-WQ2671MR IVTScrip™ mRNA-Anti-TNFRSF10B, AMG 655(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AMG 655
GTTS-WQ3338MR IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AT-001
GTTS-WQ291MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ14422MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ10329MR IVTScrip™ mRNA-Anti-ERBB3, LJM716(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LJM716
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW